Cochlear Limited (COH.AX) said that it has received U.S. Food and Drug Administration approval of Cochlear Nucleus Implants for the treatment of unilateral hearing loss or UHL/single-sided deafness or SSD.
UHL is classified as hearing loss in one ear and near to near-normal hearing in the opposite ear, and SSD is specific to individuals with severe to profound hearing loss in one ear and normal or near-normal hearing in the other ear.
Cochlear noted that it will now support those with UHL/SSD by offering its cochlear implant, the Cochlear Nucleus System, and bone conduction solutions, the Cochlear Osia System and the Cochlear Baha System.
Cochlear's implantable hearing solutions restore access to sound to improve quality of life and meet the lifestyle needs and preferences of each individual recipient.
For comments and feedback contact: editorial@rttnews.com
Business News